Fuller & Thaler Asset Management
ACAD icon

Fuller & Thaler Asset Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Fuller & Thaler Asset Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-73
Closed -$1.35K – 563
2024
Q1 		$1.35K Sell
73
-641,112
-100% -$15.9M ﹤0.01% 533
2023
Q4 		$20.1M Buy
+641,185
New +$15.3M 0.1% 203
2018
Q4 		– Sell
-437,255
Closed -$9.08M – 460
2018
Q3 		$9.08M Buy
+437,255
New +$6.88M 0.09% 166

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Fuller & Thaler Asset Management's ACAD Position: Q2 2024 in Review

Fuller & Thaler Asset Management sold out of Acadia Pharmaceuticals (ACAD) in Q2 2024, closing a stake of 73 shares — an estimated $1.35K sold.

Fuller & Thaler Asset Management first reported a position in ACAD in Q3 2018 and held it in 3 quarters. The position peaked at $20.1M in Q4 2023. 264 funds tracked by Wall St. Rank hold ACAD as of Q2 2024.

  • Fuller & Thaler Asset Management reported no remaining Acadia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Fuller & Thaler Asset Management sold 73 Acadia Pharmaceuticals shares in Q2 2024, an estimated $1.35K.
  • Fuller & Thaler Asset Management first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 3 quarters.
  • Fuller & Thaler Asset Management's Acadia Pharmaceuticals position peaked at $20.1M in Q4 2023.
  • 264 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2024.

Based on Fuller & Thaler Asset Management's 13F filing for Q2 2024, filed 9 Aug 2024.